Cardiff Oncology Announces New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival – Yahoo Finance

– 12 of 35 (34%) patients treated per protocol at the recommended Phase 2 dose (RP2D) in combination with FOLFIRI and bevacizumab achieved a complete response or partial response (CR: 1 patient; PR: 11 patients)
– 17 of 48 (35%) patients across all dose levels achieved a CR or PR. Historically, objective response rates (ORR) of 5-13% have been reported in similar second line patient populations treated with various different drug combinations, including the standard of care chemotherapy of FOLFIRI with bevacizumab1-4
– 5 of 48 (10%) patients discontinued the trial to pursue potentially curative metastasis-directed therapy (surgical resection or microwave ablation)
– Median progression-free survival (mPFS) across all response-evaluable patients (n=48) is 9.4 months and has not yet been reached in those treated per protocol at the RP2D. Historically, mPFS of ~4.5-5.7 months has been reported in a similar patient population treated with standard of care chemotherapy of FOLFIRI with bevacizumab1-4
– The combination regimen of onvansertib plus FOLFIRI/bevacizumab is well tolerated with no major or unexpected toxicities attributed to onvansertib
– Company management is hosting a webcast and conference call today at 5:00 PM ET
SAN DIEGO, Jan. 18, 2022 /PRNewswire/ — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced new data from its lead clinical program evaluating onvansertib in combination with standard-of-care (SOC) FOLFIRI/bevacizumab for second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC). A subset of these data will be featured in a poster presented by Dr. Heinz-Josef Lenz, principal investigator, USC Norris Comprehensive Cancer Center, at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCOGI) on Saturday, January 22, 2022.
"As we have increased the number of patients evaluated and the duration of follow-up, our Phase 1b/2 trial has consistently generated data suggesting that onvansertib provides meaningful clinical benefits when added to SOC," said Katherine L. Ruffner, M.D., chief medical officer of Cardiff Oncology. "The objective response rate and median progression free survival observed substantially exceed what would be expected with SOC alone, and five patients receiving onvansertib have been able to pursue potentially curative metastasis-directed treatments. We also observed a confirmed complete response, which is exciting given the difficult-to-treat nature of second line mCRC patients."
The most current data for the trial are shown below and include patient follow up collected after the cutoff dates for both the ASCO-GI abstract and poster (one additional PR was recorded after December 3):
Efficacy data in evaluable patients (represents an update from ASCO-GI abstract/poster):
Among patients treated per protocol at the recommended Phase 2 dose (RP2D; 15 mg/m2) in combination with FOLFIRI-bev:
Patients evaluable for response treated at all dose levels (12 mg/m2, 15 mg/m2, 18 mg/m2)
Status of 4 unconfirmed PRs:
5 of 48 (10%) evaluable patients discontinued therapy to pursue potentially curative metastasis-directed therapy (surgery or microwave ablation), including 2 patients with SD
Median progression free survival (mPFS; no update from ASCO-GI poster)
mPFS has not yet been reached in patients treated per protocol at the RP2D
mPFS across all response-evaluable patients (n = 48) is 9.4 months (95% confidence interval: 7.1 – not yet reached)
mPFS of ~4.5-5.7 months has been reported in trials used as historical controls1-4
Biomarker data across all patients (no update from ASCO-GI poster):
Responses (CRs or PRs) were observed across seven different KRAS mutation variants, including the 3 most commonly observed in colorectal cancer (G12D, G12V, G13D)
Patients achieving a best response of a CR or PR showed the greatest decreases in plasma KRAS mutant allelic frequency (MAF) measured by droplet digital PCR (ddPCR) after 1 cycle (28 days) of therapy
Safety data across all patients (no update from ASCO-GI poster):
The combination of onvansertib and FOLFIRI/bevacizumab was shown to be well-tolerated with only 11% (84/788) of reported treatment-emergent adverse events (TEAEs) being G3/G4
Baseline characteristics of patients at all dose levels (no update from ASCO-GI poster):
The patients' median age was 61 years (range 35-83), and 56% were male
67% patients had previously received bevacizumab
16 of 48 (33%) evaluable patients remain on trial at the data cutoff date
Mark Erlander, Ph.D., chief executive officer of Cardiff Oncology, commented, "These impressive results show radiographic responses across multiple KRAS mutation variants when onvansertib is combined with the standard of care regimen of FOLFIRI-bev and demonstrate a substantial increase in disease response relative to historical controls. We believe the data presented today further validate the potential of onvansertib to provide a meaningful improvement in the treatment outcome of a large patient population that has limited available treatment options. Looking forward, and with our strong cash position, we have the ability to explore the full potential of onvansertib."
Webcast and Conference Call
The newly announced data are being discussed today at 5:00 PM ET as part of a webcast and conference call with members of the Cardiff Oncology management team. To access the webcast, click here. To participate by phone, please dial 1-877-407-9208 (domestic) or 1-201-493-6784 (international) and refer to conference ID 13725845. Following the live event, an archived webcast will be available on the "Events" section of the Cardiff Oncology website.
About the Phase 1b/2 Trial of Onvansertib in the Second-Line Treatment of KRAS-mutated mCRC
This is a multi-center, single-arm, Phase 1b/2 trial of onvansertib in combination with standard-of-care FOLFIRI and Avastin® (bevacizumab) to evaluate the safety and preliminary efficacy of the combination regimen in the second-line treatment of patients with KRAS-mutated mCRC. The trial, A Phase 1b/2 Study of Onvansertib (PCM-075) in Combination with FOLFIRI and Bevacizumab for Second–Line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS Mutation, is enrolling patients with histologically confirmed metastatic and unresectable colorectal carcinoma harboring a KRAS mutation. Patients must also have experienced disease progression or treatment intolerance to first-line treatment with fluoropyrimidine and oxaliplatin (FOLFOX or CapeOx) with or without bevacizumab to be eligible. The trial is being conducted at the following cancer centers across the U.S.: USC Norris Comprehensive Cancer Center, The Mayo Clinic (Arizona, Rochester, and Jacksonville), Kansas University Medical Center (KUMC), CARTI Cancer Center and Inova Schar Cancer Institute. For more information on the trial, please visit NCT03829410.
References
Giessen et al., Acta Oncologica 2015, 54: 187-193
Cremolini et al., Lancet Oncol 2020, 21: 497–507
Antoniotti et al., Correspondence Lancet Oncol June 2020
Bennouna et al., Lancet Oncol 2013; 14: 29–37
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need. Our goal is to target tumor vulnerabilities with treatment combinations that overcome disease resistance and improve disease response to standard treatment regimens and to increase overall survival. We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 ("PLK1") inhibitor, in combination with standard-of-care anti-cancer therapeutics. Our clinical development programs incorporate tumor genomics and biomarker technology to refine assessment of patient response to treatment. We have three clinical programs currently ongoing: a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin® (bevacizumab) in KRAS-mutated metastatic colorectal cancer (mCRC); a Phase 2 trial of onvansertib in combination with nanoliposomal irinotecan, leucovorin and fluorouracil for the second-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDAC); and a Phase 2 study of onvansertib in combination with Zytiga® (abiraterone)/prednisone in metastatic castrate-resistant prostate cancer (mCRPC). For more information, please visit https://www.cardiffoncology.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Cardiff Oncology's expectations, strategy, plans or intentions. These forward-looking statements are based on Cardiff Oncology's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm our financial condition and increase our costs and expenses; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that any of our technology or products will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that any precision medicine therapeutics will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Cardiff Oncology's Form 10-K for the year ended December 31, 2020, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Cardiff Oncology does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.
Cardiff Oncology Contact:
Vicki Kelemen
Chief Operating Officer
858-952-7652
vkelemen@cardiffoncology.com
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Amy Jobe, Ph.D.
LifeSci Communications
315-879-8192
ajobe@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiff-oncology-announces-new-data-from-lead-clinical-program-in-kras-mutated-metastatic-colorectal-cancer-showing-robust-objective-response-rate-and-progression-free-survival-301463258.html
SOURCE Cardiff Oncology, Inc.
In a somewhat counterintuitive development, shares of Axsome Therapeutics (NASDAQ: AXSM) rose on Thursday even though the company pointed out several issues in the development of one of its drugs. Following the company's latest update on the affected program, one analyst reiterated his bullish outlook on the shares, and they rose by 5.5%. In a regulatory filing, Axsome said it provided an official response to the Food and Drug Administration (FDA) regarding the pending New Drug Application (NDA) its AXS-05 drug candidate.
In this article, we discuss the 10 safe tech stocks to consider for retirement. If you want to skip our detailed analysis of these stocks, go directly to the Retirement Stock Portfolio: 5 Safe Tech Stocks To Consider. There is no denying the fact that the definition of “growth” and “value” stocks has fundamentally changed […]
Nothing seems to be going right for Novavax (NASDAQ: NVAX) these days. The European Commission granted authorization to Novavax's Nuvaxovid COVID vaccine in December. On Jan. 14, HAS approved Nuvaxovid, making it the fifth COVID-19 vaccine approved in the country.
Is Pfizer stock a buy or a sell after a new study cast doubt on the need for a fourth Covid shot? Is PFE stock a buy now?
The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions. This means that investors may wait for years before knowing whether a drug under development will pay off. Many biotech companies have shifted their focus entirely or added COVID-19 vaccine and treatments to their product pipeline.
Dr. Robert G. Lahita MD, PhD, Director of the Institute for Autoimmune and Rheumatic Disease at Saint Joseph Health and author of Immunity Strong, joins Yahoo Finance Live to discuss the latest information on COVID-19 booster vaccinations, transmissibility, and the pressures felt by hospitals in remote regions.
23andMe's "absolute amazing journey" with GSK — as CEO Anne Wojcicki calls it —has pushed one drug into the clinic in more than three years.
Photo Illustration by The Daily Beast/HandoutA Minnesota woman whose husband neared death from COVID appealed to the courts to force his hospital to halt their plans to pull the plug on the man’s ventilator.Scott Quiner, 55, a reportedly unvaccinated man who had been battling COVID in Mercy Hospital’s ICU in Coon Rapids since November, was set to have his ventilator shut off on Jan. 13, according to a petition filed in court one day before the deadline by his wife, Anne Quiner.Quiner said the de
Moderna is looking to expand the use of mRNA drug technology to other vaccines. So far, investors haven't been impressed by progress on a flu shot.
D.C.’s Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) has settled a patent infringement lawsuit with a generic competitor over the local company’s key product. Vanda said Friday it has inked a license deal that puts to bed litigation against Piscataway, New Jersey’s MSN Pharmaceuticals Inc. and MSN Laboratories Private Ltd., which wanted to make a generic version of Hetlioz, Vanda’s treatment for non-24-hour sleep-wake disorder. The agreement gives a nonexclusive license to MSN and Impax Laboratories LLC of Hayward, Connecticut (part of Bridgewater, New Jersey’s Amneal Pharmaceuticals LLC), to make and commercialize a product using tasimelteon — the active ingredient in Hetlioz — starting March 13, 2035.
Preliminary research showed fourth dose of the Pfizer vaccine boosts antibodies, but did not prevent Omicron infections
SAN DIEGO, January 18, 2022 /3BL Media/ — Illumina Inc. (NASDAQ: ILMN) announced a partnership with Boehringer Ingelheim to develop companion diagnostics (CDx) for several programs in Boehringer I…
Moderna (NASDAQ: MRNA) stock has soared for the past two years thanks to its leadership in the coronavirus vaccine market. Then, they doubled down on their positions when Moderna commercialized its product and started to generate billions of dollars in revenue and profit. Considering this point, is Moderna stock too expensive?
Jenna Jameson is hospitalized with unknown illness as doctors rule out Guillain-Barré syndrome.
Dermatologist Dr. Sonia Batra shares what health issues can be discovered by a regular skin check. A red belly button can be a sign of certain cancers. Dr. Batra shares that it’s called a Sister Mary Joseph nodule. It’s most commonly related to gastrointestinal cancers but can also reveal ovarian cancer. The Number One Illness Your Dermatologist Sees Every Day
It seems like COVID is never-ending and now we're battling the latest surge, thanks in part to Omicron, the highly contagious variant that is sweeping across the country. It's been years since we've been on edge, socially distanced and worn masks, and while it's exhausting, now isn't the time to let our guard down. It's important to continue to take precautions and Eat This, Not That! Health talked with LetsGetChecked's Executive Director of Epidemiology, Dr. Gwen Murphy, Ph.D., MPH about places
The core reason is that investors are growing increasingly concerned about what the next phase of this global viral outbreak will mean in terms of demand for COVID-19 therapies and vaccines. Regardless of how the U.S. COVID-19 vaccine market plays out, though, Novavax ought to have a significant commercial opportunity for its vaccine abroad in the years ahead, especially in emerging markets.
A fourth vaccine boost lifted antibodies, but omicron infections persisted, according to an unpublished study at an Israeli hospital
A California woman said she would "definitely eat sushi again” even after suffering from a severe stomachache the day after binge-eating 32 all-you-can-eat sushi rolls, among other dishes. Danielle Shapiro, 24, shared what happened in a TikTok on Dec. 23, 2021 which she titled “All you can eat sushi gone wrong,” according to the New York Post. Shapiro went to Sushi 85, a buffet restaurant in Mountain View, California, in December 2021, when her friend Amanda was visiting from out of town, LADbible reported.
"The doctor told me there was no rush, even though the radiology report stated my tumor was 'of concern.' In fact, she was going on vacation for two weeks and her schedule was full."

source

Share this post:

Leave a Reply